Investigators from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) will discuss the latest findings from the study at 4:00 p.m. CT. Silvio E. Inzucchi, MD, will review the metabolic and safety aspects of DAPA-HF.
